

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052870 A1(51) International Patent Classification⁷: C07D 251/54,
251/70, 403/14, B01D 15/08, G01N 30/48(74) Agent: GILL JENNINGS & EVERY; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).(21) International Application Number:
PCT/GB2003/005368(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0228724.1 9 December 2002 (09.12.2002) GB
60/443,092 28 January 2003 (28.01.2003) US(84) Designated States (*regional*): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Applicant (*for all designated States except US*):
PROMETIC BIOSCIENCES LTD. [GB/GB]; Freeport,
Ballasalla, Isle of Man IM9 2AP (GB).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BURTON, Steven,
James [GB/GB]; ProMetic BioSciences Ltd, 211 Cam-
bridge Science Park, Milton Road, Cambridge CB4 0ZA
(GB). HUSSAIN, Abid [GB/GB]; Institute of Biotechnol-
ogy, University of Cambridge, Tennis Court Road, Cam-
bridge CB2 1QT (GB). PEARSON, James, Christopher
[GB/GB]; ProMetic BioSciences Ltd, 211 Cambridge Sci-
ence Park, Milton Road, Cambridge CB4 0ZA (GB).


Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRIAZINE COMPOUNDS AND THEIR USE IN FORMING MULTIDIMENSIONAL LIBRARIES FOR AFFINITY
CHROMATOGRAPHY


(I)



(a)

(57) Abstract: A compound of the formula (I) wherein each Z is the same or different and is formula (a) or -Y wherein each X is
the same or different and is a multivalent aminyl group or diaminyl-terminated spacer; each Y is the same or different aminyl group;
and M is a support matrix.

7. A compound of the formula



wherein Z is as defined in claim 1.

8. A method for the synthesis of a compound according to any of claims 1 to 6, which comprises the reaction of a compound according to claim 7 with an amine-containing support matrix.
9. A method for the synthesis of a compound according to claim 7, which comprises the reaction of a dichlorotriazine sequentially with an aminyl group Y, a group X, cyanuric chloride, a second aminyl group Y and a third aminyl group.
10. A library of related compounds according to any of claims 1 to 6, e.g. on a common support M.
11. A method for the production of a library according to claim 10, which comprises the synthesis of intermediate structures, either singly or in multiples, dividing the structures into smaller portions, and carrying out appropriate subsequent reaction steps.
12. The use of a compound according to any of claims 1 to 6, for the separation, isolation, purification, characterisation, identification, quantification or discovery of peptides and proteins.
13. A process for the separation, purification or discovery of a proteinaceous material, which comprises subjecting a sample containing the material to affinity chromatography using a compound according to any of claims 1 to 6.

14. A process according to claim 13, wherein the proteinaceous material is an immunoglobulin or a subclass, fragment, precursor or derivative thereof, including fusion proteins, whether derived from natural or recombinant sources.

15. The use of a compound according to any one of claims 1 to 6, for the removal of contaminants, including toxic or pathogenic entities, from a preparation of biological or pharmaceutical compound.